CYP2C9*3
|
WikiDoc Resources for CYP2C9*3 |
|
Articles |
|---|
|
Most recent articles on CYP2C9*3 |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CYP2C9*3 at Clinical Trials.gov Clinical Trials on CYP2C9*3 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CYP2C9*3
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating CYP2C9*3 Risk calculators and risk factors for CYP2C9*3
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CYP2C9*3 |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Cytochrome P450 2C9 (CYP2C9), a member of the CYP2C enzyme subfamily, ranks amongst the most
important drug metabolizing enzymes in humans.
Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild-type protein CYP2C9*1, at least 32 single nucleotide polymorphisms (SNPs) have been reported within the coding region of the CYP2C9 gene producing the variant allozymes. CYP2C9*3 is one of them. CYP2C9*3 reflects an Ile359-Leu (I359L) change in the amino acid sequence, and have reduced catalytic activity compared with the wild type (CYP2C9*1).
Allele frequencies(%) of CYP2C9 polymorphism
| African-American | Black-African | Pygmy | Asian | Caucasian | |
|---|---|---|---|---|---|
| CYP2C9*3 | 2.0 | 0-2.3 | 0 | 1.1-3.6 | 3.3-16.2 |